TMCnet News
Research and Markets Adds Report: Companion Diagnostics Market byTechnology, Application, & by End-user - Global Trends & Forecasts to 2019 [Manufacturing Close - Up](Manufacturing Close - Up Via Acquire Media NewsEdge) Research and Markets has announced the addition of the "Companion Diagnostics Market byTechnology, Application, & by End-user - Global Trends & Forecasts to 2019" report to its offerings. In a release, Research and Markets noted that report highlights include: The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7 percent during the forecast period (2014 to 2019). This market is segmented by technology, application, and end user. Technologies are further subsegmented into immunohistochemistry, in situ hybridization (fluoroscent ISH and chromogenic ISH), polymerase chain reaction (PCR), and next- generation sequencing (NGS)-based tests. The application market is further subsegmented into breast cancer, lung cancer, melanoma cancer, and colorectal cancer. The end users are majorly segmented into pharmaceutical companies and reference laboratories. Among technologies, the polymerase chain reaction (PCR)-based test accounted for the largest share of 65.5 percent in 2013. The growth of companion diagnostic in the other application segments (neurological diseases, infectious diseases, ovarian cancer, and leukemia) is expected to grow at a CAGR of 30.3 percent; whereas, on the basis of end user, reference laboratories is expected to grow at the fastest rate in the market. The major application driving the global companion diagnostics market is the adoption of companion diagnostic tests in oncology for various indications and for target therapies. Currently, breast, lung colorectal, and melanoma are the major types of cancer for which FDA approved companion diagnostics are available. In addition, encouragement by regulatory bodies and acceptance of tests by end users are the prominent factors for growth of market. Notable restraining factors include varied reimbursement procedures in different regions and usage of non-validated tests for identification of biomarkers. However, advanced technologies such as next-generation sequencing and growth of companion diagnostic in prostate cancer, leukemia, ovarian cancer, Alzheimer's disease, and Parkinson's disease are likely to augment the global companion diagnostic market in the future. In 2013, Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), QIAGEN N.V. (Netherlands), and Thermo Fisher Scientific Inc. (U.S.) together accounted for a share of 86 percent of the global companion diagnostics market. Company Profiles -Abbott Laboratories, Inc. -Agilent Technologies, Inc. -Biogenex Laboratories -Biomerieux -Danaher Corp. -Ge Healthcare -Myriad Genetics, Inc. -Qiagen N.V. -Roche Diagnostics -Thermo Fisher Scientific, Inc. Report information: http://www.researchandmarkets.com/research/rcg9gj/companion ((Comments on this story may be sent to [email protected])) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved. |